Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
Peramivir is a neuraminidase (NA) inhibitor (NAI) under development that must be administered by the systemic route. The prophylactic activity of intramuscular (IM) peramivir was evaluated with mice infected with wild-type (WT) and oseltamivir-resistant (H274Y NA mutant) recombinant influenza A/WSN/33 (H1N1) viruses. Treatment regimens consisted of IM injections starting 1 h before viral challenge that were single (45 mg/kg or 90 mg/kg) or multiple (45 mg/kg daily for 5 days). All peramivir regimens prevented mortality and weight loss while significantly reducing lung viral titers (LVT) in mice infected with the WT virus. For animals infected with the H274Y mutant, the multiple-dose regimen completely prevented mortality and was associated with significant reduction in weight loss and LVT compared to untreated animals. In contrast, both single-treatment regimens reduced mortality and weight loss but did not significantly reduce LVT. Although further experiments using different influenza A/H1N1 virus strains and other animal models are needed, our results suggest that 5-day IM peramivir therapy may be considered a prophylactic alternative to control influenza infections caused by oseltamivir-resistant viruses with the H274Y mutation.
Abed
Yacine
Y
Research Center in Infectious Diseases of the CHUQ-CHUL and Laval University, Québec City, Québec, Canada.
Simon
Philippe
P
Boivin
Guy
G
D000146:Acids, Carbocyclic; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002460:Cell Line; D003517:Cyclopentanes / Q000008:administration & dosage / Q000627:therapeutic use*; D004285:Dogs; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use*; D053118:Influenza A Virus, H1N1 Subtype / Q000201:enzymology* / Q000235:genetics; D007273:Injections, Intramuscular; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D009439:Neuraminidase / Q000235:genetics*; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000517:prevention & control*; D014764:Viral Proteins / Q000235:genetics*
D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; D014764:Viral Proteins; D009439:Neuraminidase; C414210:peramivir
J Infect Dis. 2010 Mar;201(5):740-5
20100088
JAMA. 2006 Feb 22;295(8):891-4
16456087
N Engl J Med. 2005 Sep 29;353(13):1363-73
16192481
Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8
11709315
Antivir Ther. 2004 Aug;9(4):577-81
15456089
Antiviral Res. 2009 Jul;83(1):90-3
19501261
JAMA. 2009 Mar 11;301(10):1034-41
19255110
Antivir Ther. 2007;12(4 Pt B):603-16
17944268
Antiviral Res. 2002 Jun;54(3):143-7
12062387
Antimicrob Agents Chemother. 2001 Mar;45(3):749-57
11181355
Antivir Ther. 2005;10(8):901-10
16430195
N Engl J Med. 2005 Dec 22;353(25):2667-72
16371632
N Engl J Med. 2009 Dec 3;361(23):2296-7
19907034
Antiviral Res. 2006 Jan;69(1):39-45
16325932
Antiviral Res. 2006 Jun;70(2):1-16
16513187
J Med Chem. 2000 Sep 21;43(19):3482-6
11000002
Antimicrob Agents Chemother. 2009 Feb;53(2):791-3
19015327